Cannabis Use Disorder

Effective interventions for adolescent Cannabis Use Disorder (CUD) often involve a combination of individual and family therapy approaches. Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) have demonstrated efficacy in individual settings, helping adolescents explore their ambivalence towards cannabis use and develop coping mechanisms to manage cravings and triggers. Family-based interventions, such as Multidimensional Family Therapy (MDFT) and Brief Strategic Family Therapy (BSFT), address family dynamics that may contribute to or exacerbate CUD. These therapies focus on improving communication, setting boundaries, and developing positive parenting skills. Consider implementing a combination of these approaches tailored to the individual adolescent's needs and family context. Explore how integrating contingency management, which involves rewarding abstinence with positive reinforcement, can further enhance treatment outcomes. Learn more about specific therapy protocols and adaptations for adolescents with co-occurring mental health conditions.

Differentiating between recreational cannabis use, problematic use, and CUD requires careful assessment using the DSM-5 criteria. Recreational use typically involves infrequent consumption without significant impairment or negative consequences. Problematic use indicates a pattern of cannabis use that leads to adverse consequences in one or more life domains (e.g., relationships, work, school) despite the absence of a full CUD diagnosis. CUD, however, is diagnosed when an individual exhibits at least two of the eleven DSM-5 criteria within a 12-month period. These criteria include symptoms such as tolerance, withdrawal, craving, using more cannabis than intended, neglecting major roles to use cannabis, and continued use despite social or interpersonal problems. In a primary care setting, clinicians can utilize screening tools like the CUDIT (Cannabis Use Disorders Identification Test) to quickly assess risk and then follow up with a more comprehensive clinical interview to determine the severity and presence of specific DSM-5 criteria. Explore how incorporating validated questionnaires and clinical interviews can improve the accuracy of CUD diagnosis in busy primary care settings.

While no medications are currently FDA-approved specifically for CUD, several pharmacological options are being investigated and used off-label to manage specific symptoms associated with CUD, such as withdrawal and cravings. These may include medications like N-acetylcysteine (NAC), gabapentin, and certain antidepressants. For patients with co-occurring disorders like anxiety or depression, clinicians must carefully consider potential drug interactions and choose medications that address both CUD symptoms and the co-occurring condition. For example, certain antidepressants may help manage both depression and cannabis cravings, but their efficacy and suitability must be evaluated on a case-by-case basis. Consider implementing a shared decision-making approach when discussing treatment options with patients, carefully weighing the benefits and risks of each medication in the context of their individual health profile and co-occurring disorders. Learn more about emerging research on novel pharmacological treatments for CUD and best practices for managing co-occurring conditions.